NATIONAL INSTITUTE FOR HEALTH AND CARE **EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Mepolizumab for treating severe refractory eosinophilic asthma

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?
 - access to tertiary care centres, and
 - identifying all appropriate patients (who may not present with typical symptoms).
- 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

Neither of these issues represents a potential equality issue that could be addressed by the Committee. Access to tertiary care is an implementation issue and identifying appropriate patients is a clinical issue.

Have any other potential equality issues been identified by the 3. Committee, and, if so, how has the Committee addressed these?

No other potential equality issues were identified by the Committee.

4.	Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?	
No		
5.	Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?	
No		
6.	Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?	
No		
7.	Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?	
Not applicable		

Approved by Associate Director (name): Melinda Goodall

Date: 23/09/15

Second consultation

2 of 6

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

The company stated that the age used in the company's model was based on the trial and representative of English clinical practice. The company stated that "non-guidance on the basis that a small number of patients at either extreme of the age distribution may be less cost effective runs the risk of depriving the target population we believe would be inequitable."

The committee did not consider this to be an equalities issue. The committee noted that the population in England is likely to be younger than the trial population, and also noted that exploring this had a marginal impact on results.

No other potential equality issues were identified.


2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

N/A

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

N/A

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?



5. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

The summary table notes that no equalities issues were identified.

Approved by Associate Director (name): Melinda Goodall

Date: 31/05/2016

4 of 6

Final Appraisal Determination

1.	Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?	
No potential equality issues were identified.		
2.	Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?	
N/A		
3.	Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?	
N/A		
4.	Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?	
N/A		
5.	Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?	
N/A		

Technology appraisals: Guidance development
Equality impact assessment for the single technology appraisal of mepolizumab for treating severe refractory eosinophilic asthma 5 of 6

6.	Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
N/A	

7. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

The summary table notes that no equalities issues were identified

Approved by Programme Director (name): ...M. Boysen.....

Date: 23/11/2016

6 of 6